

Electronic supplementary material

ESM 5. AscAA growth rates stratified by type of chemotherapy YES vs. NO

		annual aneurysm growth rate (mm/y)							t-Test	Wilcoxo	n
		Min	Q1	Median	Mean	Q3	Max	SD	p	n p	
Alkylating agents	YES	-1.83	0	0	0.16	0.37	1.96	0.61	0.74	0.54	53
	NO	-1.83	0	0.12	0.2	0.35	2.21	0.66			92
Anti-metabolites	YES	-1.57	0	0	0.23	0.37	1.96	0.72	0.71	0.71	29
	NO	-1.83	0	0.06	0.17	0.35	2.21	0.63			116
Mitotic inhibitors	YES	-0.95	0	0	0.08	0.26	1.01	0.40	0.14	0.40	37
	NO	-1.83	0	0	0.22	0.41	2.21	0.71			108
Anti-androgens	YES	-1.10	0	0.2	0.21	0.44	1.81	0.62	0.83	0.29	35
	NO	-1.81	0	0	0.18	0.34	2.21	0.65			110
GnRH-Agonists	YES	-1.83	0	0.13	0.02	0.29	1.81	0.66	0.14	0.57	30
	NO	-1.83	0	0	0.23	0.4	2.21	0.64			115
Corticosteroids	YES	-0.95	0	0	0.22	0.41	2.21	0.58	0.76	0.99	21
	NO	-1.83	0	0	0.18	0.35	2.13	0.66			124
Monoclonal antibodies	YES	-0.22	0	0	0.19	0.24	0.90	0.35	0.98	0.67	14
	NO	-1.83	0	0	0.18	0.36	2.21	0.67			131
Topoisomerase inhibitors	YES	-1.57	0	0.11	0.28	0.50	1.96	0.92	0.73	0.61	10
	NO	-1.83	0	0	0.18	0.35	2.21	0.62			135
Antra-cycline	YES	-0.37	0	0	0.29	0.48	1.96	0.58	0.47	0.87	15
	NO	-1.83	0	0	0.17	0.35	2.21	0.65			130
Kinase inhibitors	YES	0	0	0.16	0.24	0.49	0.77	0.28	0.52	0.45	13
	NO	-1.83	0	0	0.18	0.34	2.21	0.67			132
VEGF inhibitors	YES	0.37	0.40	0.43	0.43	0.46	0.49	0.09	0.0498	0.14	2
	NO	-1.82	0	0	0.18	0.35	2.21	0.65			143
Immune checkpoint inhibitors	YES	0	0	0.15	0.11	0.16	0.29	0.12	0.28	0.88	9
	NO	-1.83	0	0	0.19	0.40	2.21	0.67			136
PSMA-Ligand	YES	-1.09	-0.51	0.18	0.01	0.38	1.01	0.63	0.30	0.81	14
	NO	-1.83	0	0	0.20	0.35	2.21	0.65			131
IMiDs	YES	0	0	0	0.13	0.18	0.61	0.22	0.56	0.71	8
	NO	-1.82	0	0	0.19	0.37	2.21	0.66			137
Antifolates	YES	0	0	0	0	0	0	0	0.0007	0.36	2
	NO	-1.83	0	0	0.19	0.36	2.21	0.65			143
Aromatase inhibitors	YES	0	0	0	0	0	0	/	/	/	1
	NO	-1.82	0	0	0.19	0.36	2.21	0.65			144
HIFU	YES	0.20	0.20	0.20	0.20	0.20	0.20	/	/	/	1
	NO	-1.83	0	0	0.18	0.36	2.21	0.65			144

Notes. Abbreviations: n = number of patients per group; SD = standard deviation; Q1 = 1. quartile; Q3 = 3. quartile; mm = millimeter; y = year; GnRH = gonadotropin-releasing hormone; VEGF = vascular endothelial growth factor; PSMA = prostate-specific membrane antigen; IMiDs = immunomodulatory imide drugs; HIFU = high intensity focused ultrasound. p-value is based on student t-test; p<0.05 is considered significant and marked bold.